OCULAR THERAPEUTIX, INC Costs and Expenses in USD from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Ocular Therapeutix, Inc quarterly/annual Costs and Expenses history and growth rate from 2014 to Q3 2025.
  • Ocular Therapeutix, Inc Costs and Expenses for the quarter ending September 30, 2025 was $83.2M, a 35.5% increase year-over-year.
  • Ocular Therapeutix, Inc Costs and Expenses for the twelve months ending September 30, 2025 was $307M, a 51.3% increase year-over-year.
  • Ocular Therapeutix, Inc annual Costs and Expenses for 2024 was $236M, a 67.2% increase from 2023.
  • Ocular Therapeutix, Inc annual Costs and Expenses for 2023 was $141M, a 8.2% increase from 2022.
  • Ocular Therapeutix, Inc annual Costs and Expenses for 2022 was $130M, a 7.07% increase from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Growth (%)

OCULAR THERAPEUTIX, INC Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $307M $83.2M +$21.8M +35.5% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $285M $81.1M +$21.1M +35.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $264M $74.6M +$28.2M +60.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q4 2024 $236M $67.7M +$32.8M +94.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $203M $61.4M +$27.1M +79.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $176M $60M +$24.3M +67.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $151M $46.4M +$10.5M +29.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q4 2023 $141M $34.9M +$1.41M +4.23% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $139M $34.3M +$786K +2.35% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $139M $35.8M +$3.57M +11.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $135M $35.9M +$4.9M +15.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $130M $33.4M +$3.08M +10.1% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 $127M $33.5M +$1.83M +5.77% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $125M $32.2M +$233K +0.73% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $125M $31M +$3.45M +12.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $122M $30.4M +$8.67M +40% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 $113M $31.7M +$11.8M +59.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $101M $31.9M +$12.5M +64.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $88.6M $27.6M +$8.35M +43.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $80.3M $21.7M -$1.97M -8.31% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $82.2M $19.9M -$4.09M -17.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $86.3M $19.5M -$2.8M -12.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $89.1M $19.2M -$927K -4.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $90M $23.7M +$5.87M +33% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $84.2M $24M +$8.66M +56.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $75.5M $22.2M +$8.04M +56.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $67.5M $20.2M +$6.36M +46.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $61.1M $17.8M +$4.58M +34.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $56.5M $15.3M -$405K -2.58% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $56.9M $14.2M -$4.57M -24.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $61.5M $13.8M -$2.35M -14.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $63.8M $13.2M +$220K +1.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $63.6M $15.7M +$6M +61.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $57.6M $18.8M +$7.23M +62.6% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $50.4M $16.1M +$5.18M +47.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $45.2M $13M Oct 1, 2016 Dec 31, 2016 10-K 2019-03-07
Q3 2016 $9.72M -$1.89M -16.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $11.5M +$1.45M +14.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $11M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q3 2015 $11.6M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $10.1M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09

OCULAR THERAPEUTIX, INC Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $236M +$94.7M +67.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $141M +$10.7M +8.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $130M +$8.59M +7.07% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 $122M +$41.3M +51.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-11
2020 $80.3M -$9.78M -10.9% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-06
2019 $90M +$28.9M +47.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $61.1M -$2.74M -4.29% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 $63.8M +$18.6M +41.2% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $45.2M +$5.27M +13.2% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 $39.9M +$12.1M +43.4% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $27.9M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.